Current perspectives on the treatment of primary chronic ITP in adults
Current perspectives on the treatment of primary chronic ITP in adults
Dr David J. Kuter, Prof. Pål Andrè Holme, Dr Vickie McDonald, Prof. Jerzy Windyga
Understand how treatment for primary chronic immune thrombocytopenia (ITP) in adults has evolved, hear current perspectives on the treatment of ITP in the COVID-19 era and look into the future with world-class expertsDr David J. Kuter
Haematologist
Massachusetts General Hospital and Harvard Medical School
United States (US)
Prof. Pål Andrè Holme
Haematologist
Oslo University Hospital
Norway
Dr Vickie McDonald
Haematologist
Royal London Hospital and Queen Mary University of London
United Kingdom (UK)
Prof. Jerzy Windyga
Haematologist
Institute of Hematology and Transfusion Medicine
Poland
Dr David J. Kuter
Haematologist
Massachusetts General Hospital and Harvard Medical School
United States (US)
Prof. Pål Andrè Holme
Haematologist
Oslo University Hospital
Norway
Pål Andrè Holme is Professor of Haematology and Senior Haematologist at the Department of Haematology and Institute of Clinical Medicine, Oslo University and Oslo University Hospital, Rikshospitalet, Norway. He graduated from the Medical School at the University of Oslo in 1993 and was a research fellow at the Institute for Internal Medicine, University of Oslo, where he earned a PhD in 1996 after studies on platelet activation and platelet-derived-microparticle formation. He is a specialist in internal medicine and haematology. Prof. Holme has been responsible for the treatment of adult patients with haemophilia and bleeding related disorders in Norway since 2006. He leads a research group at Institute of Clinical Medicine and participates in several clinical research groups and has for a long time been an active investigator in studies on bleeding related disorders and platelets, and has authored many papers published in peer-reviewed journals and textbook chapters on these subjects.
Prof. Pål Andrè Holme has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Bayer, Octopharma, Pfizer, Sobi and Takeda.
Dr Vickie McDonald
Haematologist
Royal London Hospital and Queen Mary University of London
United Kingdom (UK)
Dr Vickie McDonald is a consultant haematologist at the Royal London Hospital, London, UK. Her main interests are disorders of coagulation, including ITP. She looks after patients with inherited and acquired disorders of clotting and platelets and runs specialist clinics in ITP. She is an honorary senior lecturer at Queen Mary University of London and is the national chief investigator for the UK ITP registry in addition to the PI and CI for several trials in ITP, both early and late phase studies.
Dr Vickie McDonald has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Abbvie, Amgen, Grifols, Novartis and Sobi.
Prof. Jerzy Windyga
Haematologist
Institute of Hematology and Transfusion Medicine
Poland
Jerzy Windyga is the Head of the Department of Disorders of Haemostasis and Internal Medicine in the Institute of Haematology and Transfusion Medicine, Warsaw, Poland. Prof. Windyga obtained his medical degree from Warsaw Medical University. He later received his doctoral degree at the Institute of Haematology and Blood Transfusion in Warsaw, where he also completed his medical specialisations in internal medicine, haematology, and laboratory haematology. He has been a member of the Board of Directors of the WFH (2014-2018) and the Executive Board of the Polish Society of Haematology and Transfusion Medicine (2011-2019). He was the 2012–2016 chair of the Haemophilia Twinning Committee of the WFH. Dr Windyga has also been a member of the EUHANET Steering Committee. In 2013 Dr Windyga was the president of the 6th Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). Since 2003, Professor Windyga has been a member of the Medical Board of the Polish Haemophilia Society, where he advises on recommendations for haemophilia management. In 2019 he has been appointed the Chair of the Advisory Board of the National Program of Haemophilia and Allied Disorders in Poland 2019-2023. He has authored and co-authored over 400 papers published both in Polish and international medical journals. His current research is focused on management of haemophilia and other inherited bleeding disorders, immune thrombocytopenia, thrombotic microangiopathies, porphyria as well as management of venous thromboembolism with a focus on thrombophilia and rare venous thromboses.
Prof. Jerzy Windyga has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Jerzy Windyga has no relevant financial disclosures
Webinar |
60 min
|accreditation:
EBAC |
Jul 2020
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
This CME-accredited symposium took place during the ISTH virtual congress on 14th July 2020.
The broader educational objectives of this programme are:
- Review of the current standard of care in ITP, detailing its risk and benefit
- Explain the mechanism of action and clinical data of potential new and innovative therapeutic options in ITP
- Comparison of standard of care today and in the future
The live event 'Current Perspectives on the Treatment of Primary Chronic ITP in Adults' took place during ISTH 2020 on 14th July 2020 and has been accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. Please note: CME credit can only be claimed for attending the live event on 14th July 2020.
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credit™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website https://edhub.ama-assn.org/pages/applications. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
This educational programme is being planned and implemented according to the EBAC accreditation requirements and policies. The programme will be certified for 1 CME credit. Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.
Other programmes of interest
Other programmes developed by Prof. Pål Andrè Holme
Other programmes developed by Dr Vickie McDonald
Dr Vickie McDonald
Haematologist
Royal London Hospital and Queen Mary University of London
United Kingdom (UK)
Other programmes developed by Prof. Jerzy Windyga
Prof. Jerzy Windyga
Haematologist
Institute of Hematology and Transfusion Medicine
Poland